BLA 125164 · Hoffman-La Roche
Mircera
Methoxy Polyethylene Glycol-Epoetin Beta · Injection
NovelLast checked: Nov 20, 2026Latest source record: Jun 4, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2007
Nov 14, 2007
Approved uses
n/a
Original approval plus efficacy supplements
Registered trials
87
53 Phase 3, 1 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
No approvals could be loaded from Drugs@FDA just now.
Clinical trials
Interventional ClinicalTrials.gov studies with "Methoxy Polyethylene Glycol-Epoetin Beta" as an intervention, any sponsor and status, largest first.
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT00773513 · 2,825 participants · Start Dec 12, 2008 · Primary completion Jul 27, 2017
Drug: Darbepoetin Alfa; Epoetin Alfa and 2 more · For: Chronic Renal Anemia
Sites: Buenos Aires, Argentina; CABA, Argentina; Gosford, Australia · 196 sites in all
- Vafseo Outcomes In-Center ExperiencePivotal-lookingCompleted
USRC Kidney ResearchResearch network
NCT06520826 · 2,116 participants · Start Nov 20, 2024 · Primary completion Sep 10, 2026
Drug: Vadadustat; Erythropoiesis Stimulating Agent · For: Anemia of Chronic Kidney Disease
Sites: Lone Tree, Colorado; Dalton, Georgia; Gallup, New Mexico · 5 sites in all
- A Study of Intravenous or Subcutaneous Methoxy Polyethylene Glycol-Epoetin Beta (RO0503821, Mircera) in Chronic Kidney Disease Patients With Renal AnemiaPivotal-lookingCompleted
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT00090753 · 1,228 participants · Start Oct 2004 · Primary completion Dec 2009
Drug: Methoxy Polyethylene Glycol-Epoetin Beta; Epoetin alfa and 2 more · For: Anemia
Sites: Birmingham, Alabama; Mobile, Alabama; Montgomery, Alabama · 249 sites in all
- Study to Evaluate the Efficacy and Safety of Roxadustat in the Treatment of Anemia in Participants With ESRD on Stable DialysisPivotal-lookingCompleted
Kyntra BioIndustry
NCT02273726 · 741 participants · Start Jan 15, 2015 · Primary completion Sep 19, 2018
Drug: Epoetin Alfa; Roxadustat · For: CKD Anemia in Stable Dialysis Patients
Sites: Phoenix, Arizona; Pine Bluff, Arkansas; Chula Vista, California · 76 sites in all
- A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis PatientsPivotal-lookingCompleted
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT00077610 · 673 participants · Start Feb 2004 · Primary completion Aug 2005
Drug: Epoetin alfa or beta; RO0503821 (1x/2 Weeks) and 1 more · For: Anemia
Sites: Birmingham, Alabama; Mobile, Alabama; Montgomery, Alabama · 99 sites in all
- A Study of Subcutaneous Mircera for the Treatment of Anemia in Dialysis Patients.Pivotal-lookingCompleted
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT00077623 · 572 participants · Start Mar 2004 · Primary completion Sep 2005
Drug: epoetin alfa or beta; methoxy polyethylene glycol-epoetin beta (Mircera) and 1 more · For: Anemia
Sites: Hot Springs, Arkansas; Los Angeles, California; Riverside, California · 90 sites in all
- A Study of Mircera for the Maintenance Treatment of Anemia in Dialysis PatientsPivotal-lookingCompleted
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT00394953 · 490 participants · Start Dec 2006 · Primary completion Nov 2008
Drug: Darbepoetin alfa; methoxy polyethylene glycol-epoetin beta [Mircera] · For: Anemia
Sites: Adelaide, Australia; Clayton, Australia; Gosford, Australia · 88 sites in all
Akebia TherapeuticsIndustry
NCT04707768 · 456 participants · Start Jun 18, 2021 · Primary completion Jan 6, 2023
Drug: Vadadustat; Mircera® · For: Anemia Associated With Chronic Kidney Disease (CKD)
Sites: Huntsville, Alabama; Phoenix, Arizona; Pine Bluff, Arkansas · 58 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis.
Chung EY, Palmer SC, Saglimbene VM, et al. · Cochrane Database Syst Rev 2023 · Systematic Review, Research Support, Non-U.S. Gov't
- Methoxy polyethylene glycol-epoetin beta versus darbepoetin alfa for anemia in non-dialysis-dependent CKD: a systematic review.
Alsalimy N, Awaisu A · Int J Clin Pharm 2014 · Comparative Study, Systematic Review
- Subcutaneous C.E.R.A. for the Maintenance Treatment of Anemia in Pediatric Patients With CKD: A Phase 2, Open-Label, Single-Arm, Multicenter Study.
Warady BA, Meyer Reigner S, Tirodkar C, et al. · Am J Kidney Dis 2023 · Multicenter Study, Clinical Trial, Phase II
- Non-Inferiority of Subcutaneous Efepoetin Alfa Compared to Methoxy Polyethylene Glycol-Epoetin Beta in Stage 3 or 4 CKD Patients: Insights From a Phase 3 Trial.
Roger SD, Wong CM, Vejakama P, et al. · Nephrology (Carlton) 2025 · Multicenter Study, Clinical Trial, Phase III
- Treatment of anemia with epoetin in kidney transplant recipients.
Bren A, Arnol M, Kandus A, et al. · Ther Apher Dial 2011 · Comparative Study, Controlled Clinical Trial
- Efficacy and Long-Term Safety of C.E.R.A. Maintenance in Pediatric Hemodialysis Patients with Anemia of CKD.
Fischbach M, Wühl E, Reigner SCM, et al. · Clin J Am Soc Nephrol 2018 · Clinical Trial, Phase II, Multicenter Study
Sponsor: Hoffman-La Roche
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.